Burning Rock Biotech Spon Ads Each Rep 10 Ord Cl A R/s (BNR) Stock
Cancer testing company guiding hospital treatment decisions. Here's the price, business snapshot, and what's worth knowing about Burning Rock Biotech Spon Ads Each Rep 10 Ord Cl A R/s in October 2026.
Burning Rock Biotech Ltd (BNR) is a molecular diagnostics company focused on precision oncology. It develops and commercialises next‑generation sequencing (NGS) tests and related services to help guide cancer diagnosis, treatment selection and monitoring — including tissue and circulating tumour DNA (ctDNA) assays. Investors should note its relatively small market capitalisation (about $109M) and that growth depends on test adoption by hospitals and clinics, reimbursement environment, regulatory approvals and partnerships with drugmakers and healthcare providers. Like many diagnostics companies, revenue can be cyclical and results may be lumpy as new products scale. Key risks include competition, regulatory changes, and dependence on relationships in core markets. This summary is for general educational purposes only and is not personal investment advice; values can rise or fall and past performance does not guarantee future returns.
Burning Rock Biotech Spon Ads Each Rep 10 Ord Cl A R/s (BNR) Stock Forecast
Analyst price target, next 12 months
$3.78
-75.6% vs today's $15.49
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Burning Rock Biotech Spon Ads Each Rep 10 Ord Cl A R/s have a consensus 12-month target of $3.78, below the current price of $15.49.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend selling Burning Rock Biotech's stock, indicating a belief that it may lose value.
Financial Health
Burning Rock Biotech is performing well with solid revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption of NGS
NGS tumour profiling is increasingly used to match patients with targeted therapies, which could support revenue growth — though adoption varies by region and reimbursement.
Liquid Biopsy Momentum
ctDNA tests offer less invasive monitoring and early detection potential; promising market tailwinds exist, but clinical validation and payer support are still evolving.
Market & Regulation
Performance depends on regulatory approvals, hospital relationships and geographic expansion; regulatory or reimbursement shifts can materially affect outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
